Floatz logo

177lu-rad204

PDL1 Gene Mutation

Radiopharm Theranostics, LtdradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the PDL1 Gene Mutation cohort.

Asset / SponsorPhaseRating
Serplulimab
Zhejiang Cancer Hospital
Phase 2CCC
Durvalumab
Fundación GECP
D

Same molecule, other indications

177lu-rad204 is also rated in:

small cell lung carcinomaDormant
C
Indicative ·
39 / 100
View asset →
triple-negative breast carcinomaDormant
C
Indicative ·
39 / 100
View asset →
Mmr DeficiencyDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →